ResTorbio pivots pipeline with reverse-merger after trial failure
April 29, 2020 at 14:15 PM EDT
Boston biopharma startup resTORbio Inc. is revamping its pipeline to focus on cancer cell therapies through a reverse-merger.
Data & News supplied by www.cloudquote.io
Stock quotes supplied by Barchart Quotes delayed at least 20 minutes. By accessing this page, you agree to the following Privacy Policy and Terms and Conditions. |
|